Zentalis Says Intermittent Azenosertib Monotherapy Dosing Nearly Doubles Efficacy Over Continuous Dosing; The Confirmed Objective Response Rate Was 36.8% In The Combined Ovarian Cancer And Uterine Serous Carcinoma Subgroups
Portfolio Pulse from Benzinga Newsdesk
Zentalis Pharmaceuticals announced that intermittent dosing of Azenosertib monotherapy nearly doubled its efficacy compared to continuous dosing, with a confirmed objective response rate of 36.8% in combined ovarian cancer and uterine serous carcinoma subgroups.

June 06, 2023 | 10:04 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Zentalis Pharmaceuticals' Azenosertib monotherapy demonstrated increased efficacy with intermittent dosing, potentially benefiting the company's stock price.
The announcement of increased efficacy in Azenosertib monotherapy with intermittent dosing is a positive development for Zentalis Pharmaceuticals. This could lead to increased investor interest and a potential rise in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100